Skip to content
10-Q

Quarterly Report

Hemab Therapeutics Holdings, Inc. COAG

0001193125-26-234386

← back to feed
Filed
May 21, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 46.71M sh
Shares Diluted Q1 2026 · Mar 31, 2026 946K sh
Shares Diluted Q1 2026 · Mar 31, 2025 946K sh
Capex Q1 2026 · Mar 31, 2026 $112K
Capex Q1 2026 · Mar 31, 2025 $16K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.58M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.03M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $49.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $87.97M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$198.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$176.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $13.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.68M
Total Liabilities Q1 2026 · Mar 31, 2026 $13.71M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.25M
Current Assets Q1 2026 · Mar 31, 2026 $169.43M
Current Assets Q1 2026 · Dec 31, 2025 $192.55M
Total Assets Q1 2026 · Mar 31, 2026 $175.26M
Total Assets Q1 2026 · Dec 31, 2025 $194.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$23.98
Eps Diluted Q1 2026 · Mar 31, 2025 −$16.18
Eps Basic Q1 2026 · Mar 31, 2026 −$23.98
Eps Basic Q1 2026 · Mar 31, 2025 −$16.18
Sga Expense Q1 2026 · Mar 31, 2026 $4.15M
Sga Expense Q1 2026 · Mar 31, 2025 $2.46M
Rd Expense Q1 2026 · Mar 31, 2026 $19.46M
Rd Expense Q1 2026 · Mar 31, 2025 $14.1M
Net Income Q1 2026 · Mar 31, 2026 −$22.69M
Net Income Q1 2026 · Mar 31, 2025 −$15.31M
Operating Income Q1 2026 · Mar 31, 2026 −$23.61M
Operating Income Q1 2026 · Mar 31, 2025 −$16.56M